Theregen`s Anginera PatchUsed as Foundation forBeating Heart Cell Patch

SAN FRANCISCO--(Business Wire)--
Theregen, Inc. (www.theregen.com) has announced that its Anginera heart patch, a
living three-dimensional engineered human tissue, was used as the foundation for
the "living band-aid for the heart" reported recently at the 2009 American Heart
Association (www.americanheart.org) Cardiovascular Sciences Conference in Las
Vegas, NV.

Views of the beating heart tissue are available courtesy of NPR ScienceFriday at
http://www.theregen.com/heartbeat_popup.html.

Anginera, an epicardial patch containing living human fibroblast cells and
extracellular matrix, induces arteriogenesis, repair and restoration of regional
heart function. The heart cells embedded in the Anginera tissue scaffold were
derived from rat heart tissue. Researchers Steven Goldman, M.D. and Jordan
Lancaster, B.S., from the Southern Arizona Veterans Administration and the
University of Arizona Sarver Heart Center, reported that the Anginera patch
cultured with rat heart cells can beat in coordinated rhythm at various rates
(www.sciencefriday.com/videos/watch/10230/).

Anginera is currently in human clinical testing for cardiac applications. The
patch has demonstrated an ability to 1.) stimulate new mature blood vessels
(arteriogenesis) in the human heart in trial patients and 2.) improve left
ventricular function in animal models.

Theregen, Inc. (www.theregen.com) develops cell-based therapies for patients
with cardiac disease. Theregen's primary corporate objective is the clinical
development and approval of Anginera, its lead product candidate. Theregen is
located in San Francisco, Calif.

Theregen, Inc.
David Ringler, 925-935-5710
Corporate Communications
dringler@theregen.com

Copyright Business Wire 2009